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Abstract
Patients suffering from AIDS develop ocular complications, the most frequent being HIV retinopathy. It is however not clear,
if functional visual impairments can be observed as early indicators of ocular complications, before clinical diagnosis of HIV
retinopathy is made at fundus examination. To address this issue, we measured colour vision in a group of 49 AIDS subjects with
normal clinical fundi using the ‘two equation method’. This method, combining red-green Rayleigh and the blue-green Moreland
metameric matches, enables more complete and quantitative assessments of colour vision than those based on pigmentary tests.
Data were collected on our computer controlled colorimeter and compared to those of normal subjects. While most AIDS subjects
without HIV retinopathy demonstrated normal colour vision, a significant portion of them had wider matches than normal
subjects (11% for the Rayleigh equation and 16% for the Moreland equation). Furthermore, matching ranges of the Moreland
equation were significantly correlated with CD4 lymphocyte counts. Patients with low CD4 values tended to produce larger
matching ranges than the patients with high CD4 values. A within subject study on 17 patients confirmed this trend and showed
that the patients who increased:decreased their CD4 blood counts generally improved:impaired their colour discrimination in the
Moreland match. No such correlation was found between the matching ranges of the Rayleigh equation and the CD4 counts.
These results show that colour discrimination is slightly reduced in some AIDS subjects, although there are no detectable ocular
complications. They also suggest two different types of colour vision impairments in AIDS patients without retinopathy: one
reversible process affecting colour discrimination in the blue-green range; and another irreversible process affecting colour
discrimination in the red-green range. © 1998 Elsevier Science Ltd. All rights reserved.
Keywords: AIDS; Colour discrimination; Colour matching; Colour vision testing
1. Introduction
Since 1982, it has become obvious that 90% of the
patients suffering from Acquired Immunodeficiency
Syndrome (AIDS) develop ocular complications [1].
Among ocular manifestations, HIV retinopathy repre-
sents the most common manifestation observed in these
patients and is clinically detected in approximately two
thirds of them [2]. Some studies have demonstrated that
these anomalies are present in all patients when tested
by fluorescein angiography or at post-mortem examina-
tion [3,4]. It remains unclear, however, if HIV retinopa-
thy is the consequence of an infection of the vascular
endothelium by HIV, the consequence of vascular dam-
age resulting from circulating immune complexes, the
consequence of an abnormal retinal blood flow, or a
mixture of these.
Recently various authors have reported deficits in
colour vision in AIDS patients. Quiceno et al. [5] found
significantly higher error scores for the Farnsworth
100-Hue test in AIDS patients than in patients with
AIDS related complex, HIV-positive patients or normal
controls. They did not identify a specific axis for these
colour vision impairments but correlated them with
HIV retinopathy. Geier et al. [6] confirmed this obser-
vation when they found a clear correlation between
colour contrast sensitivity in all three axis and the
severity of HIV retinopathy (number of cotton wool
spots). They also found (weaker) correlations between
Walter Reed staging and colour contrast sensitivity, or
between CD4 lymphocyte counts and colour contrast
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Fig. 1. Colour vision in 49 AIDS patients. MR vs. MMP. The triangle indicates the region of possible results. The rectangle at the bottom
indicates the region of normal results. Results lying outside the rectangle are considered as abnormal colour vision results.
sensitivity. Finally, Kozak and Bullimore [7] found that
even HIV-positive patients without HIV retinopathy
can have S-cone:tritanopic abnormalities. Possible ex-
planations for the mechanisms leading to such colour
vision impairment were largely discussed in these pa-
pers but no certain etiologic factor has been determined
up to now. However, colour vision impairments in
patients with normal clinical fundi may be early indica-
tors for upcoming ocular involvement in AIDS disease.
The aim of this study was to find out whether
measurable modifications of colour vision in AIDS
patients without clinical HIV retinopathy could be ob-
served using the ‘two equation method’. This method,
which combines the red-green Rayleigh equation and
the blue-green Moreland equation, is based on
metameric colour matches [8,9]. It was demonstrated
[10–13] that metameric matches enable more powerful
quantitative assessments of normal and defective colour
vision than pseudo-isochromatic or arrangement tests
(e.g. Farnsworth 100-Hue, Ishihara plates or tests on
computer graphics systems).
2. Methods
2.1. Subjects
49 Patients (13 females and 36 males, 94 eyes) with
AIDS attending the HIV:AIDS Clinic of the Geneva
University Hospital participated in this study. Age
ranged from 29 to 49 years (mean and median age 37
years). CD4 lymphocyte counts ranged from 4 cells:ml
to 600 cells:ml (median 70 cells:ml). All patients were
Caucasians except two of Afro-Caribbean origin.
The patients were selected on the basis of two com-
plete ocular examinations (visual acuity, slit-lamp
biomicroscopy, tonometry, and direct and indirect oph-
thalmoscopy) performed by one of us (EB). The first
examination enabled us to preselect patients showing
no ocular complication. The second examination, per-
formed one month later, served as a control and only
patients showing no ocular complication at both exam-
inations were included in the study. At the time of
participation in this study, none of them had an acute
opportunistic infection anywhere and all of them had
normal clinical fundi. Inclusion criteria were: (1) age of
18 years or more; (2) visual acuity of 0.8 or better; and
(3) normal clinical fundi. Exclusion criteria were: (1) a
history of congenital or acquired eye disease; (2) dia-
betes; (3) drug abuse; (4) myopia demanding a correc-
tion of more than 3D; and (5) other diseases
influencing colour vision (e.g. vascular eye diseases
related to arterial hypertension or sudden hearing loss).
Informed consent was obtained for each patient and a
good motivation for the test was demanded. When
tested all patients were on customized individual anti-
retroviral therapy such as Bactrim® (trimethoprim-sul-
famethoxazole), Retrovir® (AZT) (Geier et al. [14]
reported in a case report on two patients a temporary
alteration of tritan colour contrast sensitivity at the
beginning of Zidovudine (AZT) treatment; none of our
patients was at the beginning of an AZT treatment),
3TC® (Lamivudine), Zerit® (Stavudine) or Hivid® (Zal-
citabine) and some of them received protease inhibitors
such as Invirase® (Saquinavir), Norvir® (Ritonavir) or
Crixivan® (Indinavir).
All patients had one full colour vision examination.
Furthermore, we asked the patients to come back for a
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Fig. 2. Histograms for the MMP of 49 AIDS patients. A normal distribution is fitted to the data and compared with the distribution for normal
subjects.
second test to investigate possible individual changes in
their colour vision. Only 17 patients (34 eyes) out of 49
actually came back for a second examination. The time
between the first and second test varied from 2 to 20
months.
2.2. Colour 6ision assessment and statistical analysis
All colour vision tests were conducted by the same
person (JS) on our laboratory computer-controlled
anomaloscope (a commercial version of this instrument
is now available from Interzeag AG (Schlieren, Switzer-
land) but the 7° observation field size is however not yet
implemented in this miniaturised instrument) with four
independent light channels [15]. The Rayleigh equation
(670545589 nm) on a 2° circular observation field
was always tested first. Afterwards the Moreland equa-
tion (490436desaturated 480 nm) was tested on a
7° observation field. After each colour vision test the
optical density of the crystalline lens was measured with
the Lens Opacitometer 701™ (the Lens Opacitometer
701™ is available from Interzeag, Switzerland; for more
technical details see [16]) to exclude colour vision im-
pairment due to abnormal optical lens density.
The colour vision testing procedure was exactly iden-
tical to the one used for a previous normal population
study [17] (a more detailed description of the testing
procedure itself and the statistical analysis of the sub-
ject’s responses can be found in [18,19]). The result of
the colour vision test are two values expressed on a
0–100 scale: the match-mid-point (MMP), assessing the
perceptual relationship between the colours defined by
the mixture field primaries (used to equalize the refer-
ence primary), and the matching range (MR) assessing
colour discrimination around the reference primary.
The data of the previous normal population study
(100 subjects, mean age 29 years) were used to establish
reference distributions and limits for normal subjects.
Student’s t-test was used to assess the statistical signifi-
cance of differences between group means, while the
F-test was used to compare variances of group distribu-
tions. The significance of correlations between CD4
blood counts and colour vision results was tested using
correlation coefficient testing [20].
3. Results
The results of our colour vision measurements on the
AIDS subjects are summarized in Fig. 1 (the MMP
values of our reference normal population were slightly
shifted towards the lower wavelength primary, primar-
ily to compensate for the mean age difference of 8 years
between the AIDS patients and the normal subjects; for
the influence of age on colour vision results see [21–
23]). While most AIDS patients without retinopathy
had normal colour vision, 10 (11%) out of 92 eyes
exceeded the normal limits in the Rayleigh equation
and 15 (16%) out of 92 eyes exceed the normal limits in
the Moreland equation. Surprisingly, only 3 eyes
showed abnormal results in both equations. Since the
normal limits were computed to be exceeded in only 5%
(by definition) of the cases in a normal population,
abnormal results appear to be slightly more frequent in
our AIDS patient data. More detailed statistical analy-
sis were done to see if this trend was significant.
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Fig. 3. Histograms for the log MR of 49 AIDS patients (the finite size of the smallest steps in the iterative algorithm determining the MR results
in artefactual clustering of data for extremely small matching ranges, therefore we ignored these data before fitting log MR with a normal
distribution which explains the empty lower parts under the fitted normal distributions). A normal distribution is fitted to the data and compared
with the corresponding distribution for normal subjects.
3.1. MMP
Histograms of all the MMP values measured on the
AIDS subjects are presented in Fig. 2 [18,19]. These
data were fitted to a normal-distribution and compared
to those obtained (by exactly the same procedure) on
normal subjects. There is no statistically significant
difference between the MMP distributions, either for
the Rayleigh equation (unpaired t-test P0.36) or for
the Moreland equation (unpaired t-test P0.69).
3.2. MR
Histograms of the MR values measured on the AIDS
subjects are presented in Fig. 3. These data were fitted
to a log-normal distribution (for more details concern-
ing our data analysis using log-normal distributions see
[17]). Comparisons with the distributions obtained
(with exactly the same procedure) on normal subjects
reveal that the AIDS patients had significantly larger
MRs on both equations (unpaired t-test P0.028 for
the Rayleigh equation; P0.002 for the Moreland
equation). A close look at the fitted curves shows that
the log MR distribution for the Moreland equation is
simply shifted towards higher values, while the log MR
distribution of the Rayleigh equation is not only
slightly shifted towards higher values but also signifi-
cantly larger than the log MR distribution for the nor-
mal subjects (F-test P0.006).
3.3. Correlation with the CD4 blood count
The only parameter which was found to be signifi-
cantly correlated with the CD4 lymphocyte counts is
the MR of the Moreland equation (Fig. 4a, PB0.05)
(we could not find any significant correlation between
colour vision results and other parameters, such as best
corrected visual acuity or lens opacity). Patients with
low CD4 values have a tendency to produce larger
MRs than patients with high CD4 values. Moreover,
for the 17 patients tested twice, we found a significant
correlation between the DMR of the Moreland equa-
tion and DCD4 counts (Fig. 4b, P0.01), confirming
the correlation between the MR of the Moreland equa-
tion and the CD4 blood counts. CD4 count improve-
ment results generally in MR improvement. It is
interesting to note that in the case of these 17 patients,
we have a within subject study where individual vari-
ability of colour vision does not smear out the results.
4. Discussion
This study shows a slight impairment of colour vision
in some AIDS patients with normal clinical fundi. In
these cases, the effect of the HIV disease is essentially
reflected by a reduced colour discrimination in the
Moreland and:or the Rayleigh equations. Our results
for the Moreland equation confirm earlier results by
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Fig. 4. (a) Log MR for the Moreland equation vs. CD4 lymphocyte counts (artificially low MR values were uniformly fixed at a MR value of 0.4
units; there is no change in significance if we ignore these data when computing the regression). CD4 values are indicated on a logarithmic scale.
(b) Log MR change in the Moreland equation vs. CD4 count change for 17 AIDS patients. Positive values indicate higher values at the second
examination (positive DCD4 values improvement of the CD4 lymphocyte counts; negative D log MR values improvement of colour
discrimination).
Kozak and Bullimore [7] who found reduced S-cone
contrast sensitivity for HIV patients without clinical
signs and a very recent study of Muller et al. [24] who
have reported an elevated error scores for the
Farnsworth–Munshell 100-Hue test in HIV patients
without HIV retinopathy.
We found significant correlations between the CD4
blood count values and colour discrimination in the
Moreland equation: (1) in all tested patients, higher
CD4 blood counts were significantly correlated with
better colour discrimination; and, (2) in the 17 patients
tested twice, improvements:impairments in CD4 blood
counts were significantly correlated to improvements:
impairments of colour discrimination. Geier et al. [6]
had found a significant correlation between CD4 blood
counts and tritan:protan colour contrast sensitivity in a
group of subjects including patients with HIV retinopa-
thy, while Mueller et al. [24] did not find any significant
correlation between Farnsworth 100-Hue error scores
and CD4 blood counts in their subjects without HIV
retinopathy. The discrepancy of our results with the
latter study is probably due to the lesser sensitivity and
specificity of the Farnsworth 100-Hue test.
The observed colour vision impairment in AIDS
patients without HIV retinopathy and the correlation
between their MR results for the Moreland equation
and CD4 lymphocyte counts can not indicate the exact
mechanisms leading to HIV retinopathy. Some medica-
ments are known to affect colour vision [25]. Although
the medication might cause the observed impairments
in colour discrimination, this is very unlikely, because
increases in CD4 blood counts were correlated with
improved colour discrimination. Furthermore, these
improvements suggest that the pathological processes
affecting colour vision could be (at least partially)
reversible.
While colour vision was impaired in a similar number
of patients in the Rayleigh and in the Moreland equa-
tion, it is interesting to note that only 3 cases had
abnormal colour vision results in both equations.
Moreover, in contrast to the Moreland equation, colour
discrimination in the Rayleigh equation was not signifi-
cantly correlated with the CD4 counts. As a conse-
quence, one may postulate two types of colour vision
impairment in AIDS patients without HIV retinopathy:
one process, affecting colour discrimination in the
Moreland equation, which is reversible; and a second
process, affecting colour discrimination in the Rayleigh
equation, which is apparently irreversible (a learning
process would not only affect the Moreland equation
but also the Rayleigh equation and it would not be
correlated to CD4 counts, thus, a learn effect can
therefore be excluded). This hypothesis needs to be
confirmed by more measurements and the long term
follow up of AIDS patients.
Impairment of colour vision can be an indicator for
subsequent ocular complications. Early detection of
such ocular complications is becoming more and more
important since successful research in AIDS treatment
leads to longer life expectation for these patients.
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